Search
Telaprevir
go.drugbank.com/drugs/DB05521ApprovedWithdrawnTelaprevir was available as a fixed dose product (tradename Incivek) used for the treatment of chronic Hepatitis C. … Telaprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotype 1 [FDA Label].
Fingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigationalIt was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.
Mosunetuzumab
go.drugbank.com/drugs/DB15434ApprovedInvestigational[rituximab] in patients with follicular lymphoma,[A249320,L42230] and unlike CAR-T therapies such as [axicabtagene ciloleucel] and [tisagenlecleucel], it is an “off-the-shelf” alternative, readily available
Ecamsule
go.drugbank.com/drugs/DB09534ApprovedEcamsule has been approved for use in the U.S. since 2006, but only at a specific concentration and only in a few products manufactured by L'Oreal.
Metandienone
go.drugbank.com/drugs/DB13586ApprovedWithdrawnIt was introduced to the market in the 1960s but later discontinued and withdrawn from the market. … Although it is prohibited in and outside competition by the World Anti-Doping Agency, metandienone continues to be marketed and misused as a performance-enhancing drug in sports.
Tolrestat
go.drugbank.com/drugs/DB02383ApprovedWithdrawnIt was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death.
Sevoflurane
go.drugbank.com/drugs/DB01236ApprovedInvestigationalVet approved[A249885] Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. … [L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996.
Telavancin
go.drugbank.com/drugs/DB06402ApprovedInvestigationalTelavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospita...
Zolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigational[L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]